E
Eleva
Leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins
About Eleva
Eleva Biologics is a pioneering startup operating in the pharmaceutical industry. The company collaborates with pharmaceutical partners to develop drug candidates, with a focus on advancing these into clinical stages. Eleva Biologics operates in a unique niche, using Bryophyta, commonly known as moss, to produce biological compounds. This innovative approach allows the company to create complex and demanding proteins, opening up new avenues for unprecedented therapies.
The company's business model is based on partnerships with pharmaceutical companies. Together, they develop complex proteins into potential drugs of the future. Eleva Biologics also works on unlocking the potential of difficult compounds that have previously failed to get expressed. Additionally, the company explores opportunities in other promising fields, developing enzymes and other proteins into clinical stages.
Eleva Biologics' revenue generation strategy is rooted in its technology platform, which remains the property of the company. New individual assets are developed in cooperation with pharmaceutical partners, and each partnership is taken into a newly formed subsidiary. This approach allows the company to monetize its innovative moss-based technology while also fostering collaboration and shared success with its partners.
In summary, Eleva Biologics is a forward-thinking biotech startup that leverages the power of moss to develop new therapies. It operates in a partnership model, working with pharmaceutical companies to bring new drug candidates to the clinical stage.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1999
- Headquarters
- Freiburg, Germany
- Employees
- 87
- Open positions
- 1
- Dealroom signal
- 82.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2021 | $66M | $264M | D11Z. Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Eleva is 1.2K monthly website visits, down 76% over the last three months. Eleva's team grew 4.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
D11Z. Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eleva on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eleva’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.